美国安进地舒单抗在哪买的到？

It can block the formation of multinucleated giant cells, thereby inhibiting the pathological process of osteolysis and destruction of giant cell tumors of bone and restoring bone formation. Desosumab is an antibody against humanized RANKL, and has been clinically proven to have a good anti-tumor effect on giant cell tumors of bone. So, where can I buy Amgen denosumab in the United States?

Desosumab has not yet been included in the medical insurance in China. Overseas, a box of denosumab produced by Amgen in the United States is only about $1,500. Compared with the same period last year, the price of the original research drug sold in China has dropped. Patients in need can purchase medicines abroad or obtain medicines through domestic professional overseas medical service organizations (such as Medical Companion Travel), which can be delivered directly to their homes to ensure authenticity.

Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. As a leader in the global biopharmaceutical industry, Guizhou has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry.

Desosumab, a monoclonal antibody drug developed by the American company Amgen that targets the RANKL protein, can competitively bind to the RANKL protein and play an effect similar to OPG, thereby inhibiting osteoclast differentiation and activation mediated by the RANKL-RANK-OPG signaling pathway, reducing osteoclast activity, and improving bone mass and quality.

Desosumab is easy to use and can be injected subcutaneously by the patient at 60 mg/time with an interval of 6 months. Subcutaneous injection of denosumab has greatly improved patients' medication compliance. At present, many authoritative guidelines at home and abroad have unanimously affirmed its status in breast cancer bone metastasis, recommending that denosumab should be started after the diagnosis of breast cancer bone metastasis.